Glinka Juan, Diaz Federico, Alva Augusto, Mazza Oscar, Sanchez Claria Rodrigo, Ardiles Victoria, de Santibañes Eduardo, Pekolj Juan, de Santibañes Martín
Department of General Surgery, Hepato-Bilio-Pancreatic Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Department of Radiation Oncology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Radiat Oncol J. 2018 Sep;36(3):210-217. doi: 10.3857/roj.2018.00206. Epub 2018 Sep 30.
Pancreatic cancer (PC) has not changed overall survival in recent years despite therapeutic efforts. Surgery with curative intent has shown the best long-term oncological results. However, 80%-85% of patients with these tumors are unresectable at the time of diagnosis. In those patients, first therapeutic attempts are minimally invasive or surgical procedures to alleviate symptoms. The addition of radiotherapy (RT) to standard chemotherapy, ergo chemoradiation, in patients with locally advanced pancreatic cancer (LAPC) is still controversial. The study aims to compare outcomes in patients with a double bypass surgery due to LAPC treated or not with RT.
A retrospective cohort study of patients with double bypass for LAPC were registered and divided into two groups: treated or not with postoperative RT. Baseline characteristics, postoperative complications, those related to RT and their relation to the main event (mortality) were compared.
Seventy-four patients were included. Surgical complications between the groups did not offer significant differences. Complications related to RT were mostly mild, and 86% of patients completed the treatment. Overall survival at 1 and 2 years for patients in the exposed group was 64% and 35% vs. 50% and 28% in the non-exposed group, respectively (p = 0.11; power 72%; hazard ratio = 0.53; 95% confidence interval, 0.24-1.18).
We observed a tendency for survival improvement in patients with postoperative RT. However, we've not had enough power to demonstrate this difference, possibly due to the small sample size. It is indispensable to develop randomized and prospective trials to guide more specific treatment lines in this patients.
尽管进行了多种治疗努力,但近年来胰腺癌(PC)的总体生存率并未得到改善。根治性手术已显示出最佳的长期肿瘤学效果。然而,80%-85%的此类肿瘤患者在诊断时无法切除。对于这些患者,首次治疗尝试是采用微创或手术方法来缓解症状。在局部晚期胰腺癌(LAPC)患者中,在标准化疗基础上加用放疗(RT),即放化疗,仍存在争议。本研究旨在比较因LAPC接受或未接受RT治疗的双旁路手术患者的预后。
对因LAPC接受双旁路手术的患者进行回顾性队列研究,将其分为两组:接受或未接受术后RT治疗。比较两组的基线特征、术后并发症、与RT相关的并发症及其与主要事件(死亡率)的关系。
共纳入74例患者。两组间手术并发症无显著差异。与RT相关的并发症大多较轻,86%的患者完成了治疗。暴露组患者1年和2年的总生存率分别为64%和35%,而非暴露组分别为50%和28%(p = 0.11;检验效能72%;风险比 = 0.53;95%置信区间,0.24 - 1.18)。
我们观察到术后接受RT治疗的患者有生存改善的趋势。然而,我们没有足够的检验效能来证明这种差异,可能是由于样本量较小。开展随机前瞻性试验以指导这类患者更具体的治疗方案是必不可少的。